Articles From: CyrusOne to House First-Ever Colocated 911-Dispatch Center to Czech Industrial Output Contracts in August, Reflects Vacation at Key Car Makers


Global colocation solutions provider CyrusOne (NASDAQ: CONE) is pleased to announce that it plans to house the infrastructure and 911-dispatch center for Carrollton, Coppell, Farmers Branch, and Addison, Texas.
Sign-up for CyrusOne to House First-Ever Colocated 911-Dispatch Center investment picks
Global data center provider CyrusOne (NASDAQ: CONE) is pleased to announce that Josh Snowhorn , CyrusOne vice president and general manager, interconnection, has been elected to the Open-IX Association’s board of directors.
Sign-up for CyrusOne’s Josh Snowhorn Elected to Open-IX Board of Directors investment picks
CYS Investments, Inc. (NYSE: CYS) (the "Company") today announced that it will host a conference call at 9:00 AM Eastern Time on Tuesday, October 21, 2014, to discuss its financial results for the quarter ended September 30, 2014.
Sign-up for CYS Investments, Inc. Announces Conference Call to Discuss Third Quarter 2014 Results investment picks
CYS Investments, Inc. (NYSE: CYS) (“CYS”, "we", "our", or the “Company”) today announced financial results for the quarter ended June 30, 2014.
Sign-up for CYS Investments, Inc. Announces Second Quarter 2014 Financial Results investment picks
The Board of Directors of CYS Investments, Inc. (NYSE: CYS) (the “Company”) today declared a quarterly dividend of $0.30 per share of common stock for the third quarter of 2014.
Sign-up for CYS Investments, Inc. Board of Directors Declares Third Quarter 2014 Common Stock Dividend of $0.30 Per Share, and Preferred Stock Dividends investment picks
CYS Investments, Inc. (NYSE: CYS) ("CYS" or the "Company") today announced that Kevin E.
Sign-up for CYS Investments, Inc. to Present at Barclays Global Financial Services Conference investment picks
CYS Investments, Inc. (NYSE: CYS) ("CYS" or the "Company") today announced that Kevin E.
Sign-up for CYS Investments, Inc. to Present at JMP Financial Services and Real Estate Conference investment picks
GAITHERSBURG, Md., Aug.
Sign-up for Cytomedix to Report Second Quarter 2014 Financial Results on Thursday, August 14, 2014 investment picks
Cytori Therapeutics (NASDAQ: CYTX) today announced that Mr.
Sign-up for Cytori Appoints a New Vice President of Finance and Chief Financial Officer investment picks
Cytori Therapeutics (NASDAQ: CYTX) today announced that six month outcomes from a 12 patient independent investigator-initiated study using Cytori Cell Therapy to treat scleroderma have been published in the Annals of Rheumatic Disease .
Sign-up for Cytori Cell Therapy Reduces Hand Disability and Pain in Scleroderma Patients investment picks
Cytori Therapeutics (NASDAQ: CYTX) today announced its updated strategy and plan to restructure its operations and reduce costs.
Sign-up for Cytori Consolidates and Restructures Its Operations, Provides Business Update investment picks
Cytori Therapeutics (NASDAQ: CYTX) has consolidated its EU operations to a new European office combined with a manufacturing facility in Deeside, Wales, UK.
Sign-up for Cytori Consolidates European Operations to Newly Opened Welsh Manufacturing Facility investment picks
Cytori Therapeutics (NASDAQ: CYTX) has placed enrollment in the ATHENA and ATHENA II trials on clinical hold and therefore anticipates that it will not be possible to complete enrollment of the ATHENA I trial prior to the end of 2014 as previously anticipated.
Sign-up for Cytori Provides Update on ATHENA Trial Status investment picks
Cytori Therapeutics (NASDAQ: CYTX) today reports its second quarter 2014 financial results and provides updates on clinical development and commercialization activities.
Sign-up for Cytori Reports Second Quarter 2014 Business and Financial Results investment picks
The Cardiovascular Cell Therapy Research Network (CCTRN), has selected Cytori (NASDAQ: CYTX) Therapeutics, Inc. to supply adipose-derived regenerative cells (ADRCs™) for a clinical trial aimed at evaluating the safety and feasibility of treating patients with Left Ventricular Assist Devices (LVADs). The CCTRN is supported by grants from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). This trial, named CELLVAD-ADRC, will explore outcomes following administration of a regenerative cell preparation from adipose tissue into the patient’s heart muscle 60 to 90 days after placement of an LVAD.
Sign-up for Cytori Technology Selected for NHLBI Funded Trial in LVAD Patients investment picks
Cytori Therapeutics, Inc. (NASDAQ: CYTX) has been selected to participate in a U.S. trade mission to Japan and South Korea led by the U.S. Secretary of Commerce Penny Pritzker.
Sign-up for Cytori Therapeutics Invited to Participate in Trade Mission to Asia with U.S. Secretary of Commerce investment picks
Cytori Therapeutics, Inc. (NASDAQ: CYTX) entered into a definitive securities purchase agreements to raise an aggregate of $13.5 million in a registered direct offering, with net proceeds estimated to be approximately $12.5 million, after deducting placement agent fees and estimated offering expenses.
Sign-up for Cytori Therapeutics, Inc. to Raise $13.5 Million in Registered Direct Offering investment picks
Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its second quarter financial results and business update on Monday, August 11, 2014 at 5:00 PM Eastern Time.
Sign-up for Cytori to Webcast Second Quarter Financial Results on August 11 investment picks
LOS ANGELES , Oct.
Sign-up for CytRx Announces Unexpected Passing of Chairman Max Link, PhD investment picks
Completion of Enrollment Expected in 2015; Progression-Free Survival Data Expected in mid-2016 LOS ANGELES , Sept.
Sign-up for CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer investment picks
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus ifosfamide/mesna as a first-line treatment in subjects with various sarcomas.
Sign-up for CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Ifosfamide/Mesna as First-Line Treatment in Patients with Advanced Sarcomas investment picks
Follows CytRx's Strategy to Develop a Global Oncology Franchise in Numerous Orphan Indications LOS ANGELES , Sept.
Sign-up for CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer investment picks
CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended June 30, 2014, and also provided an overview of recent accomplishments and upcoming milestones for its clinical development programs.
Sign-up for CytRx Reports 2014 Second Quarter Financial Results investment picks
LOS ANGELES , Sept.
Sign-up for CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference investment picks
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that President and CEO Steven A.
Sign-up for CytRx to Present at Upcoming Investor Conferences in New York City and Las Vegas investment picks
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced a change in the Company’s presentation time at the at Aegis 2014 Healthcare & Technology Conference.
Sign-up for CytRx Updates Presentation Time at Aegis 2014 Healthcare & Technology Conference investment picks
Presentation and Webcast Scheduled for September 26th at 3:30 PM ET LOS ANGELES , Sept.
Sign-up for CytRx Updates Presentation Time at BioCentury's 2014 NewsMakers in the Biotech Industry Conference investment picks
2014/10/7
By Leos Rousek PRAGUE--Czech industrial output contracted in August contrary to expectations for a mild growth, confirming the economy's dependence on its automotive sector in which production declined due to holidays and retooling at key car makers, data released Tuesday by the Czech statistics office showed.
Sign-up for Czech Industrial Output Contracts in August, Reflects Vacation at Key Car Makers investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: CyrusOne to House First-Ever Colocated 911-Dispatch Center to Czech Industrial Output Contracts in August, Reflects Vacation at Key Car Makers
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices